Basel, Switzerland

Andreas Katopodis

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 5.1

ph-index = 1


Company Filing History:


Years Active: 2021-2023

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Andreas Katopodis in Immunotherapy

Introduction

Andreas Katopodis is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of immunotherapy, particularly through his work on humanized monoclonal antibodies and fusion proteins. With a total of 3 patents, his innovations are paving the way for new therapeutic applications in cancer treatment.

Latest Patents

Katopodis's latest patents include "Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof." This invention focuses on antibodies that bind to human interleukin-2 (hIL-2), specifically targeting a unique epitope of hIL-2. These antibodies inhibit the binding of hIL-2 to CD25, showcasing a novel approach to immunotherapy. Another significant patent is "Immune-stimulating IL-2 fusion proteins," which involves immune-stimulating IL-fusion proteins that comprise antibodies joined to human interleukin-2. This invention emphasizes the capability of these fusion proteins to preferentially stimulate cytotoxic T cells and NK cells compared to Treg cells, highlighting their potential in cancer treatment.

Career Highlights

Throughout his career, Katopodis has worked with prestigious institutions, including Universität Zürich and Anaveon AG. His research has focused on developing innovative solutions that enhance immune responses against cancer cells. His work has garnered attention in the scientific community, contributing to advancements in immunotherapy.

Collaborations

Some of his notable coworkers include Natalia Arenas-Ramirez and Iwan Beuvink. Their collaborative efforts have further enriched the research landscape in immunotherapy.

Conclusion

Andreas Katopodis stands out as a pioneering inventor in the field of immunotherapy, with his patents reflecting a commitment to advancing cancer treatment. His innovative approaches to humanized monoclonal antibodies and fusion proteins are set to make a significant impact in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…